石家庄市358例艾滋病患者抗逆转录病毒治疗后生存分析及危险因素研究

王莹莹; 杨海涛; 王永红; 刘淑君

doi:10.16462/j.cnki.zhjbkz.2018.03.011

石家庄市358例艾滋病患者抗逆转录病毒治疗后生存分析及危险因素研究

doi: 10.16462/j.cnki.zhjbkz.2018.03.011

1. 石家庄市疾病预防控制中心性病艾滋病防治所, 河北石家庄 050011;
2. 河北医科大学公共卫生学院流行病学与卫生统计学教研室, 河北石家庄 050017;
3. 襄阳市襄城区卧龙卫生院外科, 湖北襄阳 441101

基金项目:

河北省卫生厅重点科技研究计划（20110587）

详细信息

作者简介:
王莹莹(1979-),女,湖北襄阳人,副主任医师,硕士。主要研究方向:艾滋病性病防治。

中图分类号: R512.91;R181.2
计量
- 文章访问数: 523
- HTML全文浏览量: 97
- PDF下载量: 34
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-24
- 修回日期: 2018-01-01

Survival rate and risk factors of mortality among 358 adult HIV/AIDS patients receiving highly active antiretroviral therapy in Shijiazhuang

1. Institute for AIDS/STD Control and Prevention, Shijiazhuang Center for Disease Control and Prevention, Shijiazhuang 050011, China;
2. Department of Epidemiology and Health Statistics, School of Public Health, Hebei Medical University, Shijiazhuang 050017, China;
3. Department of Surgery, Wolong Town Clinic, Xiangcheng District, Xiangyang 441101, China

摘要

摘要: 目的研究石家庄市获得性免疫缺陷综合征（acquired immune deficiency syndrome，AIDS）患者接受高效抗反转录病毒疗法（highly active antiretroviral therapy，HAART）后的生存状态及影响因素。方法回顾性调查石家庄市2005-2013年所有初次接受治疗的成人人类免疫缺陷病毒（human immunodeficiency virus，HIV）感染者和AIDS患者，用Kaplan-Meier法估计生存率，Cox比例风险模型分析与生存状态有关的影响因素，并应用Trend F-H方法分析不同基线CD4⁺T淋巴细胞组的生存率是否存在等级差别。结果共纳入358例研究对象，治疗后总病死率为2.75/100人年，1、3、5年累积生存率分别为92%、91%、86%；基线CD4⁺T淋巴细胞数、临床分期、血红蛋白、感染途径是主要的影响因素；基线CD4⁺T淋巴细胞水平越高，死亡风险越低。结论石家庄市艾滋病抗病毒治疗效果较好，及时规范启动治疗能够提高患者生存率。
- 人类免疫缺陷病毒 /
- 艾滋病 /
- 高效抗逆转录病毒治疗 /
- 流行病学方法
Abstract: Objective To explore the survival status and risk factors among adult HIV/AIDS patients receiving highly active antiretroviral therapy (HAART) in Shijiazhuang. Methods This retrospective cohort study enrolled 358 HIV/AIDS patients receiving HAART in Shijiazhuang City from 2005 to 2013. Kaplan-Meier method was used to estimate the survival rate. Cox regression model was performed to analyze the risk factors associated with survival status. Trend F-H test was used to identify the ordinal tendency of different CD4⁺ T cell counts baseline. Results The overall mortality of 358 HIV/AIDS patients receiving HAART was 2.75/100 person-years. The 1, 3 and 5 year cumulative survival rate was 92%, 91% and 86%.The results of Cox analysis showed that baseline CD4⁺ T cell counts, clinical staging, hemoglobin and route of HIV infection are influencing factors of survival status. The trend F-H test showed that the higher baseline CD4⁺ T cell counts were associated with lower mortality risk. Conclusions The effect of HAART in Shijiazhuang is satisfactory. The early standard treatment helps to improve the survival status of HIV/AIDS patients.
- Human immunodeficiency virus(HIV) /
- Acquired immune deficiency syndrome(AIDS) /
- Highly active antiretroviral therapy (HARRT) /
- Epidemiological methods